STD Diagnostics Market Analysis By Types (Chlamydia Testing, Syphilis Testing, Gonorrhea Testing, Herpes Simplex Virus Testing, Human Papilloma Virus Testing, Human Immunodeficiency Virus Testing, Chancroid Testing), By Location Of Testing (Laboratory Testing, Point of Care Testing), By Testing Devices (Laboratory Devices, Point of Care Devices) And Segment Forecasts To 2022

Published: Jan, 2016 | Pages: 88 | Publisher: Grand View Research
Industry: Healthcare | Report Format: Electronic (PDF)

Global STD diagnostics market is expected to reach USD 200.9 billion by 2022 according to a new study by Grand View Research Inc. The rising geriatric population base, increasing global incidence of various STIs, rise in sedentary lifestyle adoption levels, and rising awareness & patient education are the driving forces for the STD diagnostics market growth over the forecast period.

Increasing number of people having multiple partners and low levels of infection awareness levels are the major drivers fueling industrial growth. Increasing demand for rapid and accurate diagnostic tests and presence of favorable government initiatives for STD testing in developing countries such as Brazil, India, and China are further estimated to boost market growth.

Further key findings from the study suggest:

Chlamydia testing accounted for over 34% of the market in 2014. Chlamydia testing for sexually active women aged below 25 years is strictly recommended by the U.S Preventive Services Task Force (PSTF). Syphilis testing is estimated to witness lucrative growth over the forecast period. It is anticipated to grow at a CAGR of 10% owing to increasing prevalence of syphilis infection globally.

On the basis of test location, laboratory testing held the largest market share of over 63% in 2014 owing to the availability of cost effective diagnostic tests used for multiple STIs at a single location such as public health labs. Point of care on the other hand is anticipated to be the fastest growing segment over the forecast period owing to the owing to the introduction of CLIA waived tests

Laboratory testing devices dominated the market in 2014 with revenue generation of over 67.0 billion. Immunochromatographic assays were most preferred devices for STD diagnosis in laboratory with revenue share of over 26%. Increasing technological advancements are estimated to enhance usage rates of thermal cyclers over the forecast period.

Portable/bench top or rapid diagnostic kits are estimated to gain demand over the forecast period owing to features such as user-friendliness, increasing awareness pertaining to self testing, and fast results.

North America held the largest share of the STD diagnostics market with revenue generation of over 32 billion in 2014. Introduction of technologically advanced diagnostics techniques such as immunochromatographic device by Chembio Diagnostics Systems Inc. is the major factor attributing for its largest market share.

Asia Pacific region is estimated to witness significant growth over the forecast period owing to the presence of high amount of target population, rising awareness levels for STIs, and increasing government initiatives and rise in disposable income expenditure levels. Asia Pacific is expected to show double digit CAGR growth over the forecast period.

Major companies of the STD diagnostics industry include Roche Holdings AG, Abbott Laboratories, Becton Dickinson and Company, Hologic Inc., Danaher Corporation, Affymetrix, BioMerieux, Cepheid Inc., Alere Inc., DiaSorin, and Orasure

Licensing and partnership deal making activities in the molecular diagnostics sector are growing significantly in terms of value. New entrants such as life science research groups, financial investors, clinical laboratories, and medical technology players drive up the values.

Table of Content

Chapter 1. Methodology and Scope
1.1. Research methodology
1.2. Research scope & assumption
1.3. List of data sources
Chapter 2. Executive Summary
2.1. STD diagnostics market - Industry Summary and Key Buying Criteria, 2012 - 2022
Chapter 3. STD Diagnostics Industry Outlook
3.1. STD diagnostics market segmentation
3.2. STD diagnostics market size and growth prospects, 2012-2022
3.3. STD diagnostics market dynamics
3.3.1. Market driver analysis
3.3.2. Market restraint analysis
3.4. Key opportunities prioritized
3.5. Industry analysis - Porter's
3.6. STD diagnostics: Company market share, 2014
3.7. STD diagnostics market PESTEL analysis, 2014
Chapter 4. STD Diagnostics Types Outlook
4.1. STD diagnostics market share by type, 2014 & 2022
4.2. Chlamydia testing market estimates and forecasts, 2012 - 2022 (USD Billion)
4.3. Syphilis testing market estimates and forecasts, 2012 - 2022 (USD Billion)
4.4. Gonorrhea testing market estimates and forecasts, 2012 - 2022 (USD Billion)
4.5. Herpes Simplex Virus testing estimates and forecasts, 2012 - 2022 (USD Billion)
4.6. Human Papilloma Virus testing market estimates and forecasts, 2012 - 2022 (USD Billion)
4.7. Human Immunodeficiency Virus testing market estimates and forecasts, 2012 - 2022 (USD Billion)
4.8. Chancroid testing market estimates and forecasts, 2012 - 2022 (USD Billion)
4.9. Other devices market estimates and forecasts, 2012 - 2022 (USD Billion)
Chapter 5. STD Diagnostics Location of Testing Outlook
5.1. STD diagnostics market share by location of testing, 2014 & 2022
5.2. Laboratory testing market estimates and forecasts, 2012 - 2022 (USD Billion)
5.2.1. Commercial/Private labs testing market estimates and forecasts, 2012 - 2022 (USD Billion)
5.2.2. Public Health Labs testing market estimates and forecasts, 2012 - 2022 (USD Billion)
5.3. Point of Care (PoC) testing market estimates and forecasts, 2012 - 2022 (USD Billion)
Chapter 6. STD Diagnostics Testing Devices Outlook
6.1. STD diagnostics market share by testing device, 2014 & 2022
6.2. Laboratory devices market estimates and forecasts, 2012 - 2022 (USD Billion)
6.2.1. Thermal Cyclers - PCR market estimates and forecasts, 2012 - 2022 (USD Billion)
6.2.2. Lateral Flow Readers market estimates and forecasts, 2012 - 2022 (USD Billion)
6.2.3. Flow Cytometers market estimates and forecasts, 2012 - 2022 (USD Billion)
6.2.4. Differential Light Scattering machines market estimates and forecasts, 2012 - 2022 (USD Billion)
6.2.5. Absorbance microplate reader - Enzyme Linked Immunosorbent Assay (ELISA) market estimates and forecasts, 2012 - 2022 (USD Billion)
6.2.6. Others market estimates and forecasts, 2012 - 2022 (USD Billion)
6.3. Point of Care (PoC) testing market estimates and forecasts, 2012 - 2022 (USD Billion)
6.3.1. Phone chips (microfluidics + ICT) market estimates and forecasts, 2012 - 2022 (USD Billion)
6.3.2. Portable/bench top/rapid diagnostic kits market estimates and forecasts, 2012 - 2022 (USD Billion)
Chapter 7. STD Diagnostics Regional Outlook
7.1. North America
7.1.1. North America market, by type, revenue (USD Billion)
7.1.1.1. U.S. market estimates and forecasts
7.1.1.2. Canada market estimates and forecasts
7.1.2. North America market, by location of testing, revenue (USD Billion)
7.1.2.1. U.S. market estimates and forecasts
7.1.2.2. Canada market estimates and forecasts
7.1.3. North America market, by testing device, revenue (USD Billion)
7.1.3.1. U.S. market estimates and forecasts
7.1.3.2. Canada market estimates and forecasts
7.2. Europe
7.2.1. Europe market, by type, revenue (USD Billion)
7.2.1.1. Sweden market estimates and forecasts
7.2.1.2. Germany market estimates and forecasts
7.2.2. Europe market, by location of testing, revenue (USD Billion)
7.2.2.1. Sweden market estimates and forecasts
7.2.2.2. Germany market estimates and forecasts
7.2.3. Europe market, by testing device, revenue (USD Billion)
7.2.3.1. Sweden market estimates and forecasts
7.2.3.2. Germany market estimates and forecasts
7.3. Asia Pacific
7.3.1. Asia Pacific market, by type, revenue (USD Billion)
7.3.1.1. China market estimates and forecasts
7.3.1.2. India market estimates and forecasts
7.3.2. Asia Pacific market, by location of testing, revenue (USD Billion)
7.3.2.1. China market estimates and forecasts
7.3.2.2. India market estimates and forecasts
7.3.3. Asia Pacific market, by testing device, revenue (USD Billion)
7.3.3.1. China market estimates and forecasts
7.3.3.2. India market estimates and forecasts
7.4. Latin America
7.4.1. Latin America market, by type, revenue (USD Billion)
7.4.1.1. Brazil market estimates and forecasts
7.4.1.2. Mexico market estimates and forecasts
7.4.2. Latin America market, by location of testing, revenue (USD Billion)
7.4.2.1. Brazil market estimates and forecasts
7.4.2.2. Mexico market estimates and forecasts
7.4.3. Latin America market, by testing device, revenue (USD Billion)
7.4.3.1. Brazil market estimates and forecasts
7.4.3.2. Mexico market estimates and forecasts
7.5. MEA
7.5.1. MEA market, by type, revenue (USD Billion)
7.5.1.1. South Africa market estimates and forecasts
7.5.2. MEA market, by location of testing, revenue (USD Billion)
7.5.2.1. South Africa market estimates and forecasts
7.5.3. MEA market, by testing device, revenue (USD Billion)
7.5.3.1. South Africa market estimates and forecasts
Chapter 8. Competitive Landscape
8.1. Becton Dickinson and company
8.1.1. Company Overview
8.1.2. Financial Performance
8.1.3. Product Benchmarking
8.1.4. Strategic Initiatives
8.2. Roche Holdings AG
8.2.1. Company Overview
8.2.2. Financial Performance
8.2.3. Product Benchmarking
8.2.4. Strategic Initiatives
8.3. Hologic Inc.
8.3.1. Company Overview
8.3.2. Financial Performance
8.3.3. Product Benchmarking
8.3.4. Strategic Initiatives
8.4. BioMerieux
8.4.1. Company Overview
8.4.2. Financial Performance
8.4.3. Product Benchmarking
8.4.4. Strategic Initiatives
8.5. Alere Inc.
8.5.1. Company Overview
8.5.2. Financial Performance
8.5.3. Product Benchmarking
8.5.4. Strategic Initiatives
8.6. Danaher Corporation
8.6.1. Company Overview
8.6.2. Financial Performance
8.6.3. Product Benchmarking
8.6.4. Strategic Initiatives
8.7. Abbott Laboratories
8.7.1. Company Overview
8.7.2. Financial Performance
8.7.3. Product Benchmarking
8.7.4. Strategic Initiatives
8.8. Affymetrix
8.8.1. Company Overview
8.8.2. Financial Performance
8.8.3. Product Benchmarking
8.8.4. Strategic Initiatives
8.9. DiaSorin
8.9.1. Company Overview
8.9.2. Financial Performance
8.9.3. Product Benchmarking
8.9.4. Strategic Initiatives
8.10. Cepheid Inc.
8.10.1. Company Overview
8.10.2. Financial Performance
8.10.3. Product Benchmarking
8.10.4. Strategic Initiatives
8.11. Orasure
8.11.1. Company Overview
8.11.2. Financial Performance
8.11.3. Product Benchmarking
8.11.4. Strategic Initiatives

List of Tables

1. STD diagnostics - Industry Snapshot
2. STD diagnostics market by type, 2012 - 2022 (USD billion)
3. STD diagnostics market by location of testing, 2012 - 2022 (USD billion)
4. STD diagnostics market by testing device, 2012 - 2022 (USD billion)
5. STD diagnostics market by region, 2012 - 2022 (USD billion)
6. STD diagnostics market - Key Market Drivers Analysis
7. STD diagnostics market - Key Market Restraints Analysis
8. North America STD diagnostics market by type, 2012 - 2022 (USD billion)
9. North America STD diagnostics market by location of testing, 2012 - 2022 (USD billion)
10. North America STD diagnostics market by testing device, 2012 - 2022 (USD billion)
11. Europe STD diagnostics market, by type, 2012 - 2022 (USD billion)
12. Europe STD diagnostics market by location of testing, 2012 - 2022 (USD billion)
13. Europe STD diagnostics market by testing device, 2012 - 2022 (USD billion)
14. Asia Pacific STD diagnostics market, by type, 2012 - 2022 (USD billion)
15. Asia Pacific STD diagnostics market by location of testing, 2012 - 2022 (USD billion)
16. Asia Pacific STD diagnostics market by testing device, 2012 - 2022 (USD billion)
17. Latin America STD diagnostics market by type, 2012 - 2022 (USD billion)
18. Latin America STD diagnostics market by location of testing, 2012 - 2022 (USD billion)
19. Latin America STD diagnostics market by testing device, 2012 - 2022 (USD billion)
20. MEA STD diagnostics market by type, 2012 - 2022 (USD billion)
21. MEA STD diagnostics market by location of testing, 2012 - 2022 (USD billion)
22. MEA STD diagnostics market by testing device, 2012 - 2022 (USD billion)